tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Regeneron announces CHMP adopts positive opinion for Libtayo
The FlyRegeneron announces CHMP adopts positive opinion for Libtayo
8d ago
REGN
Regeneron announces new, updated data from oncology pipeline
PremiumThe Fly
Regeneron announces new, updated data from oncology pipeline
10d ago
REGN
Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating
PremiumRatings
Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating
10d ago
REGN
Novo Nordisk update raises questions on Regeneron approval, says Canaccord
PremiumThe Fly
Novo Nordisk update raises questions on Regeneron approval, says Canaccord
11d ago
NVO
REGN
Regeneron price target raised to $660 from $650 at Citi
PremiumThe Fly
Regeneron price target raised to $660 from $650 at Citi
12d ago
REGN
Regeneron announces updated data for DB-OTO due to OTOF gene
PremiumThe FlyRegeneron announces updated data for DB-OTO due to OTOF gene
12d ago
REGN
Regeneron price target lowered to $756 from $761 at Morgan Stanley
Premium
The Fly
Regeneron price target lowered to $756 from $761 at Morgan Stanley
15d ago
REGN
Regeneron says FDA approves PD-1 inhibitor Libtayo
Premium
The Fly
Regeneron says FDA approves PD-1 inhibitor Libtayo
16d ago
REGN
FDA approves Regeneron’s Libtayo for cutaneous squamous cell carcinoma
PremiumThe Fly
FDA approves Regeneron’s Libtayo for cutaneous squamous cell carcinoma
16d ago
REGN
Early notable gainers among liquid option names on October 1st
PremiumThe Fly
Early notable gainers among liquid option names on October 1st
23d ago
AES
IQV
Regeneron announces U.S. FDA approved Evkeeza ANGPTL3 antibody
PremiumThe Fly
Regeneron announces U.S. FDA approved Evkeeza ANGPTL3 antibody
29d ago
REGN
Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer’s
PremiumRatings
Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer’s
29d ago
REGN
Humana initiated, Paycom upgraded: Wall Street’s top analyst calls
PremiumThe FlyHumana initiated, Paycom upgraded: Wall Street’s top analyst calls
1M ago
R
EG
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
Premium
The Fly
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
1M ago
SNY
REGN
Regeneron donates ebola treatment for use in countries at risk of outbreaks
Premium
The Fly
Regeneron donates ebola treatment for use in countries at risk of outbreaks
1M ago
REGN
Regeneron announces updated analyses from Phase 2 COURAGE trial
PremiumThe Fly
Regeneron announces updated analyses from Phase 2 COURAGE trial
1M ago
REGN
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial
PremiumThe Fly
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial
1M ago
REGN
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects
PremiumRatings
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects
2M ago
REGN
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial
PremiumThe Fly
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial
2M ago
REGN
Sandoz reaches agreement with Regeneron over patent litigation
PremiumThe FlySandoz reaches agreement with Regeneron over patent litigation
2M ago
REGN
Regeneron announces results of Phase 3 trials on allergen-blocking antibodies
Premium
The Fly
Regeneron announces results of Phase 3 trials on allergen-blocking antibodies
2M ago
REGN
Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher
Premium
The Fly
Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher
2M ago
SNY
AMGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >